Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?

Riccardo Di Fiore; Sherif Suleiman; Rosa Drago-Ferrante; Ana Felix; Sharon A. O’toole; John J. O’leary; Mark P. Ward; James Beirne; Angel Yordanov; Mariela Vasileva-Slaveva; Yashwanth Subbannayya; Francesca Pentimalli; Antonio Giordano; Jean Calleja-Agius

doi:10.3390/ijms22157829

Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?

Riccardo Di Fiore, Sherif Suleiman, Rosa Drago-Ferrante, Ana Felix, Sharon A. O’toole, John J. O’leary, Mark P. Ward, James Beirne, Angel Yordanov, Mariela Vasileva-Slaveva, Yashwanth Subbannayya, Francesca Pentimalli, Antonio Giordano, Jean Calleja-Agius

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Gynecological cancers (GCs) are currently among the major threats to female health. Moreover, there are different histologic subtypes of these cancers, which are defined as ‘rare’ due to an annual incidence of <6 per 100,000 women. The majority of these tend to be associated with a poor prognosis. Long non-coding RNAs (lncRNAs) play a critical role in the normal development of organisms as well as in tumorigenesis. LncRNAs can be classified into tumor suppressor genes or oncogenes, depending on their function within the cellular context and the signaling pathways in which they are involved. These regulatory RNAs are potential therapeutic targets for cancer due to their tissue and tumor specificity. However, there still needs to be a deeper understanding of the mechanisms by which lncRNAs are involved in the regulation of numerous biological functions in humans, both in normal health and disease. The lncRNA Mortal Obligate RNA Transcript (MORT; alias ZNF667-AS1) has been identified as a tumor-related lncRNA. ZNF667-AS1 gene, located in the human chromosome region 19q13.43, has been shown to be silenced by DNA hypermethylation in several cancers. In this review, we report on the biological functions of ZNF667-AS1 from recent studies and describe the regulatory functions of ZNF667-AS1 in human disease, including cancer. Furthermore, we discuss the emerging insights into the potential role of ZNF667-AS1 as a biomarker and novel therapeutic target in cancer, including GCs (ovarian, cervical, and endometrial cancers).

Original language	English
Article number	7829
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	15
DOIs	https://doi.org/10.3390/ijms22157829
Publication status	Published - 1 Aug 2021

Keywords

Cervical cancer
Endometrial cancer
Epigenetic therapy
Epigenetics
LncRNA-based therapy
Long non-coding RNA
MORT (ZNF667-AS1)
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms22157829

ijms-22-07829Final published version, 783 KBLicence: CC BY

Cite this

Di Fiore, R., Suleiman, S., Drago-Ferrante, R., Felix, A., O’toole, S. A., O’leary, J. J., Ward, M. P., Beirne, J., Yordanov, A., Vasileva-Slaveva, M., Subbannayya, Y., Pentimalli, F., Giordano, A., & Calleja-Agius, J. (2021). Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies? International Journal of Molecular Sciences, 22(15), [7829]. https://doi.org/10.3390/ijms22157829

Di Fiore, Riccardo ; Suleiman, Sherif ; Drago-Ferrante, Rosa ; Felix, Ana ; O’toole, Sharon A. ; O’leary, John J. ; Ward, Mark P. ; Beirne, James ; Yordanov, Angel ; Vasileva-Slaveva, Mariela ; Subbannayya, Yashwanth ; Pentimalli, Francesca ; Giordano, Antonio ; Calleja-Agius, Jean. / Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?. In: International Journal of Molecular Sciences. 2021 ; Vol. 22, No. 15.

@article{7624e45a95c94538b919b4a453bb74b4,

title = "Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?",

abstract = "Gynecological cancers (GCs) are currently among the major threats to female health. Moreover, there are different histologic subtypes of these cancers, which are defined as {\textquoteleft}rare{\textquoteright} due to an annual incidence of <6 per 100,000 women. The majority of these tend to be associated with a poor prognosis. Long non-coding RNAs (lncRNAs) play a critical role in the normal development of organisms as well as in tumorigenesis. LncRNAs can be classified into tumor suppressor genes or oncogenes, depending on their function within the cellular context and the signaling pathways in which they are involved. These regulatory RNAs are potential therapeutic targets for cancer due to their tissue and tumor specificity. However, there still needs to be a deeper understanding of the mechanisms by which lncRNAs are involved in the regulation of numerous biological functions in humans, both in normal health and disease. The lncRNA Mortal Obligate RNA Transcript (MORT; alias ZNF667-AS1) has been identified as a tumor-related lncRNA. ZNF667-AS1 gene, located in the human chromosome region 19q13.43, has been shown to be silenced by DNA hypermethylation in several cancers. In this review, we report on the biological functions of ZNF667-AS1 from recent studies and describe the regulatory functions of ZNF667-AS1 in human disease, including cancer. Furthermore, we discuss the emerging insights into the potential role of ZNF667-AS1 as a biomarker and novel therapeutic target in cancer, including GCs (ovarian, cervical, and endometrial cancers).",

keywords = "Cervical cancer, Endometrial cancer, Epigenetic therapy, Epigenetics, LncRNA-based therapy, Long non-coding RNA, MORT (ZNF667-AS1), Ovarian cancer",

author = "{Di Fiore}, Riccardo and Sherif Suleiman and Rosa Drago-Ferrante and Ana Felix and O{\textquoteright}toole, {Sharon A.} and O{\textquoteright}leary, {John J.} and Ward, {Mark P.} and James Beirne and Angel Yordanov and Mariela Vasileva-Slaveva and Yashwanth Subbannayya and Francesca Pentimalli and Antonio Giordano and Jean Calleja-Agius",

note = "Funding Information: The publication of this manuscript was funded by the European Cooperation in Science & Technology program (EU COST)?COST Action CA18117: GYNOCARE-?European Network for Gynaecological Rare Cancer Research: From Concept to Cure.? R.D.F., S.S., S.A.O., J.J.O, M.P.W., J.B., A.Y., M.V.-S., Y.S., A.G., and J.C.-A. are Action management committee members and/or form part of Working Groups 1?3, and J.C.-A. is the chairperson of this Action. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

day = "1",

doi = "10.3390/ijms22157829",

language = "English",

volume = "22",

journal = "International Journal of Molecular Sciences",

issn = "1422-0067",

publisher = "MDPI AG",

number = "15",

}

Di Fiore, R, Suleiman, S, Drago-Ferrante, R, Felix, A, O’toole, SA, O’leary, JJ, Ward, MP, Beirne, J, Yordanov, A, Vasileva-Slaveva, M, Subbannayya, Y, Pentimalli, F, Giordano, A & Calleja-Agius, J 2021, 'Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?', International Journal of Molecular Sciences, vol. 22, no. 15, 7829. https://doi.org/10.3390/ijms22157829

Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies? / Di Fiore, Riccardo; Suleiman, Sherif; Drago-Ferrante, Rosa; Felix, Ana; O’toole, Sharon A.; O’leary, John J.; Ward, Mark P.; Beirne, James; Yordanov, Angel; Vasileva-Slaveva, Mariela; Subbannayya, Yashwanth; Pentimalli, Francesca; Giordano, Antonio; Calleja-Agius, Jean.